A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
NCT ID: NCT07215312
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
100 participants
INTERVENTIONAL
2025-10-13
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LY3938577
Participants will receive LY3938577 subcutaneously (SC)
LY3938577
Administered SC
Degludec
Participants will receive degludec SC
Degludec
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY3938577
Administered SC
Degludec
Administered SC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening
* Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive
* Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tucson Clinical Research Institute
Tucson, Arizona, United States
Encompass Clinical Research
Spring Valley, California, United States
University Clinical Investigators, Inc.
Tustin, California, United States
Tampa Bay Medical Research
Clearwater, Florida, United States
Encore Medical Research
Hollywood, Florida, United States
Clinical Research of Central Florida
Lakeland, Florida, United States
Encore Medical Research - Weston
Weston, Florida, United States
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
Washington University School of Medicine
St Louis, Missouri, United States
Accellacare - Wilmington
Wilmington, North Carolina, United States
AMR Clinical
Norman, Oklahoma, United States
Tribe Clinical Research, LLC
Greenville, South Carolina, United States
Holston Medical Group
Bristol, Tennessee, United States
Texas Diabetes & Endocrinology, P.A.
Austin, Texas, United States
Velocity Clinical Research, Dallas
Dallas, Texas, United States
Juno Research
Houston, Texas, United States
Southern Endocrinology Associates
Mesquite, Texas, United States
Consano Clinical Research, LLC
Shavano Park, Texas, United States
Texas Valley Clinical Research
Weslaco, Texas, United States
Chrysalis Clinical Research
St. George, Utah, United States
CIPREC
Buenos Aires, , Argentina
Mautalen Salud e Investigación
Buenos Aires, , Argentina
Consultorio de Investigación Clínica EMO SRL
Buenos Aires, , Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, , Argentina
Instituto Centenario
CABA, , Argentina
Instituto Médico Catamarca IMEC
Rosario, , Argentina
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role: CONTACT
Phone: 317-615-4559
Email: [email protected]
Physicians interested in becoming principal investigators please contact
Role: CONTACT
Email: [email protected]
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J4P-MC-IYAC
Identifier Type: OTHER
Identifier Source: secondary_id
27409
Identifier Type: -
Identifier Source: org_study_id